Last reviewed · How we verify
cisplatin and paclitaxel
Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while paclitaxel stabilizes microtubules, preventing cell division.
Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while paclitaxel stabilizes microtubules, preventing cell division. Used for Non-small cell lung cancer, ovarian cancer, bladder cancer, head and neck cancer, and other solid tumors.
At a glance
| Generic name | cisplatin and paclitaxel |
|---|---|
| Also known as | TP |
| Sponsor | Henan Cancer Hospital |
| Drug class | Platinum-based chemotherapy, Taxane |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, which interfere with DNA repair mechanisms and induce apoptosis. Paclitaxel, on the other hand, is a taxane that binds to tubulin and prevents the disassembly of microtubules, thereby blocking cell division and leading to cell death.
Approved indications
- Non-small cell lung cancer, ovarian cancer, bladder cancer, head and neck cancer, and other solid tumors
Common side effects
- Nausea and vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
- Diarrhea
- Fatigue
- Mucositis
- Neuropathy
- Hearing loss
- Kidney damage
Key clinical trials
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer (PHASE2)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma (PHASE1, PHASE2)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cisplatin and paclitaxel CI brief — competitive landscape report
- cisplatin and paclitaxel updates RSS · CI watch RSS
- Henan Cancer Hospital portfolio CI